


PRODUCT INFORMATION



(+)-PD 128907 (hydrochloride)

Item No. 21235

CAS Registry No.: 300576-59-4
Formal Name: 3,4,4aR,10bR-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol, monohydrochloride
MF: C₁₄H₁₉NO₃ • HCl
FW: 285.8
Purity: ≥98%
UV/Vis.: λ_{max}: 228, 297 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(+)-PD 128907 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the (+)-PD 128907 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. (+)-PD 128907 (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of (+)-PD 128907 (hydrochloride) in these solvents is approximately 15 and 10 mg/ml, respectively. (+)-PD 128907 (hydrochloride) is slightly soluble in ethanol.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of (+)-PD 128907 (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of (+)-PD 128907 (hydrochloride) in PBS, pH 7.2, is approximately 0.5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

(+)-PD 128907 is a potent agonist of the dopamine 3 (D₃) receptor (K_i = 1 nM).^{1,2} It shows selectivity for D₃ over D₂ and D₄ receptors (K_is = 1.2 and 7 μM, respectively).¹ Low doses of (+)-PD 128907 (13 μg/kg, s.c.) reduce spontaneous locomotor activity in rats.³ It blocks stereotypy induced by the NMDA receptor antagonist (+)-MK-801 (Item No. 10009019) in mice.⁴ (+)-PD 128907 is used in animal models to study the role of the D₃ receptor in nervous system disorders, such as schizophrenia, Parkinson's disease, and depression.^{5,6}

References

1. Akunne, H.C., Towers, P., Ellis, G.J., et al. *Life Sci.* **57(15)**, 1401-1410 (1995).
2. Pugsley, T.A., Davis, M.D., Akunne, H.C., et al. *J. Pharmacol. Exp. Ther.* **275(3)**, 1355-1366 (1995).
3. Bristow, L.J., Cook, G.P., Gay, J.C., et al. *Neuropharmacology* **35(3)**, 285-294 (1996).
4. Witkin, J., Gasior, M., Aciri, J., et al. *Eur. J. Pharmacol.* **347(2-3)**, R1-R3 (1998).
5. Carcinella, S., Drui, G., Boulet, S., et al. *Transl. Psychiatry* **4(e401)** (2014).
6. Gil-Mast, S., Kortagere, S., Kota, K., et al. *ACS Chem. Neurosci.* **4(6)**, 940-951 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM